When it comes to determining the best treatment for overall survival in multiple myeloma, it is important to consider several factors, including the stage of the disease, the patient's overall health, and any specific genetic or molecular characteristics of the myeloma cells. Treatment decisions are typically made by a team of healthcare professionals, including hematologists, oncologists, and other specialists.

That being said, there have been significant advancements in the treatment of multiple myeloma in recent years. The standard treatment approach often involves a combination of therapies, which may include:

1. Induction therapy: This initial treatment aims to reduce the number of myeloma cells in the body. Commonly used induction therapies include combinations of chemotherapy drugs, immunomodulatory drugs (such as lenalidomide or thalidomide), and proteasome inhibitors (such as bortezomib or carfilzomib).

2. Stem cell transplantation: For eligible patients, high-dose chemotherapy followed by autologous stem cell transplantation (using the patient's own stem cells) may be recommended. This approach can help achieve deeper remission and potentially improve overall survival.

3. Maintenance therapy: After induction therapy and/or transplantation, maintenance therapy with drugs like lenalidomide or bortezomib may be prescribed to help prolong remission and improve overall survival.

4. Targeted therapies: In recent years, several targeted therapies have been approved for the treatment of multiple myeloma. These include monoclonal antibodies (such as daratumumab or elotuzumab) and other novel agents that specifically target myeloma cells or their microenvironment.

It is important to note that treatment decisions are highly individualized, and what works best for one person may not be the same for another. It is crucial to consult with a healthcare professional who can assess your specific situation and guide you towards the most appropriate treatment options.

Additionally, participating in clinical trials can provide access to new and innovative treatments that may further improve overall survival. ClinicalTrials.gov is a valuable resource to find ongoing clinical trials for multiple myeloma.

Remember, the field of multiple myeloma treatment is constantly evolving, and new therapies are being developed. It is essential to stay informed and work closely with your healthcare team to make the best decisions for your individual case.